That is my understanding from talking to the mgt team. That is...

That is my understanding from talking to the mgt team. That is they can identify specific cells, target those specific cells and deliver a toxin using EET to 'kill' only the appropriate parts without affecting any of the surrounding cells or tissues.

Compared to the current efficacy and approach that sounds like a godsend to most cancer patients and could truly change the way cancer is treated around the world. At a stretch you could almost say it's getting as close to a cure as you can get without actually reversing or permanently removing the affliction.

I wonder what that could be worth on the open market?

...and then you start thinking about the other applications such as arthritis, alzheimers, etc... the mind boggles.

BUT, where I get concerned is that no external party has yet signed up to take it on-board as part of their program. Why not? Is there something we're all missing?